Cargando…

1931. Real-world evaluation of adequacy of empiric and definitive therapy in carbapenem susceptible and non-susceptible Enterobacterales and Pseudomonas aeruginosa by time to culture result: A multicenter analysis

BACKGROUND: Infections caused by multi-drug resistant (MDR) Gram-negative pathogens are increasingly problematic in healthcare settings and are associated with worse clinical outcomes in critically ill patients. We conducted a multicenter real-world evaluation of culture turn-around time (TAT), asso...

Descripción completa

Detalles Bibliográficos
Autores principales:	Riccobene, Todd, Ai, ChinEn, Yu, Kalvin, Gregory, Sara, Lock, John L, Kim, Brooke, Gupta, Vikas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678451/ http://dx.doi.org/10.1093/ofid/ofad500.091

Ejemplares similares

180. Multicenter Analysis of Adequacy of Empiric and Definitive Therapy by Time to Culture Result in Hospitalized Patients with Blood Culture Positive for Carbapenem Resistant and Susceptible Enterobacterales and Pseudomonas aeruginosa
por: Cooper, Lauren, et al.
Publicado: (2023)

2166. Real-world susceptibilities to newer antibiotics in Enterobacterales and Pseudomonas aeruginosa including carbapenem non-susceptible and multi-drug resistant isolates : A multicenter analysis
por: Riccobene, Todd, et al.
Publicado: (2023)

588. Ceftolozane/Tazobactam Susceptibility of Carbapenem-Resistant Pseudomonas aeruginosa and Carbapenem-Resistant Enterobacterales Isolates in a Tertiary Hospital in Korea
por: Kim, Kye-Hyung, et al.
Publicado: (2023)

Characterization of Pseudomonas aeruginosa with discrepant carbapenem susceptibility profile
por: Pragasam, Agila K., et al.
Publicado: (2016)

Distinctive Regulation of Carbapenem Susceptibility in Pseudomonas aeruginosa by Hfq
por: Sonnleitner, Elisabeth, et al.
Publicado: (2020)

Carbapenem Susceptibility and Multidrug-Resistance in Pseudomonas aeruginosa Isolates in Egypt
por: Hashem, Hany, et al.
Publicado: (2016)

Genomic characterization of carbapenem-non-susceptible Pseudomonas aeruginosa in Singapore
por: Teo, Jocelyn Qi-Min, et al.
Publicado: (2021)

786. Facility Reported vs. CLSI MIC Breakpoint Comparison of Carbapenem Non-susceptible (Carb-NS) Pseudomonas aeruginosa (PSA) From 2016-2019: A Multicenter Evaluation
por: Gupta, Vikas, et al.
Publicado: (2021)

Epidemiology of carbapenem non-susceptible Pseudomonas aeruginosa isolates in Eastern Algeria
por: Meradji, Samah, et al.
Publicado: (2015)

A Multicenter Comparison of Carbapenem-Nonsusceptible Enterobacterales and Pseudomonas aeruginosa Rates in the US (2016 to 2020): Facility-Reported Rates versus Rates Based on Updated Clinical Laboratory and Standards Institute Breakpoints
por: Gupta, Vikas, et al.
Publicado: (2022)

Therapeutic Management of Pseudomonas aeruginosa Bloodstream Infection Non-Susceptible to Carbapenems but Susceptible to “Old” Cephalosporins and/or to Penicillins
por: Zaidenstein, Ronit, et al.
Publicado: (2018)

2269. Clinical Outcomes in Patients with Carbapenem-Non-Susceptible, β-Lactam-Susceptible Pseudomonas aeruginosa Infections
por: Gavaghan, Victoria M, et al.
Publicado: (2019)

2270. Initial Treatment Selection Among Patients with Recurrent Pseudomonas aeruginosa (PSA) Infections (Infxs): Does Prior PSA Antibiotic Susceptibility Results Effect Subsequent Empiric Treatment Decisions?
por: Puzniak, Laura, et al.
Publicado: (2019)

Carbapenem-resistant and cephalosporin-susceptible Pseudomonas aeruginosa: a notable phenotype in patients with bacteremia
por: Li, Shuang, et al.
Publicado: (2018)

Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa
por: Gill, Christian M, et al.
Publicado: (2022)

Correlation between Carbapenem Consumption and Carbapenems Susceptibility Profiles of Acinetobacter baumannii and Pseudomonas aeruginosa in an Academic Medical Center in Thailand
por: Paiboonvong, Taniya, et al.
Publicado: (2022)

Carbapenem-Resistant but Cephalosporin-Susceptible Pseudomonas aeruginosa in Urinary Tract Infections: Opportunity for Colistin Sparing
por: Gajdács, Márió
Publicado: (2020)

Interplay of OpdP Porin and Chromosomal Carbapenemases in the Determination of Carbapenem Resistance/Susceptibility in Pseudomonas aeruginosa
por: Atrissi, Jad, et al.
Publicado: (2021)

Mortality in patients with carbapenem-resistant Pseudomonas aeruginosa with and without susceptibility to traditional antipseudomonal β-lactams
por: Howard-Anderson, Jessica, et al.
Publicado: (2021)

A retrospective analysis of Pseudomonas aeruginosa bloodstream infections: prevalence, risk factors, and outcome in carbapenem-susceptible and -non-susceptible infections
por: Shi, Qingyi, et al.
Publicado: (2019)

716. Effect of Carbapenem-resistant vs. Carbapenem-susceptible Enterobacterales infections on patient outcomes at an academic medical center
por: Clark, Justin A, et al.
Publicado: (2023)

In Vitro Susceptibility to Ceftazidime-Avibactam and Comparator Antimicrobial Agents of Carbapenem-Resistant Enterobacterales Isolates
por: Lim, Tze-Peng, et al.
Publicado: (2023)

Carbapenem-resistant Enterobacterales susceptibility patterns to new antimicrobials: A single-center analysis
por: Monk, Miranda, et al.
Publicado: (2023)

Dissemination of transposon Tn6001 in carbapenem-non-susceptible and extensively drug-resistant Pseudomonas aeruginosa in Taiwan
por: Tseng, Sung-Pin, et al.
Publicado: (2009)

Carbapenem-resistant and cephalosporin-susceptible: a worrisome phenotype among Pseudomonas aeruginosa clinical isolates in Brazil
por: Campana, Eloiza Helena, et al.
Publicado: (2016)

Antibiotic susceptibility pattern, risk factors, and prediction of carbapenem-resistant Pseudomonas aeruginosa in patients with nosocomial pneumonia
por: Liu, Yao, et al.
Publicado: (2023)

Performance Evaluation of BD Phoenix NMIC-413 Antimicrobial Susceptibility Testing Panel for Imipenem, Meropenem, and Ertapenem Against Clinical Carbapenem-Resistant and Carbapenem-Susceptible Enterobacterales
por: Zhang, Jingjia, et al.
Publicado: (2021)

Geographical differences of carbapenem non-susceptible Enterobacterales and Acinetobacter spp. in Germany from 2017 to 2019
por: von Laer, Anja, et al.
Publicado: (2022)

Mortality associated with carbapenem-susceptible and Verona Integron-encoded Metallo-β-lactamase-positive Pseudomonas aeruginosa bacteremia
por: Persoon, Marjolein C., et al.
Publicado: (2020)

Susceptibility Rates of Pseudomonas Aeruginosa Strains to Quinolones
por: Adhikari, Luna, et al.
Publicado: (2010)

Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa
por: Papadomanolaki, Arhodoula, et al.
Publicado: (2022)

Performance of Ceftazidime-Avibactam 30/20-μg and 10/4-μg Disks for Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa
por: Han, Renru, et al.
Publicado: (2023)

Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa
por: Alosaimy, Sara, et al.
Publicado: (2021)

1080. Relebactam Increases Imipenem Activity Against Imipenem-Nonsusceptible and -Susceptible Pseudomonas aeruginosa and Enterobacterales: Assessment of Isolates from RESTORE-IMI 2
por: Hilbert, David W, et al.
Publicado: (2021)

In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model
por: Abdelraouf, Kamilia, et al.
Publicado: (2023)

Negative Impact of Citral on Susceptibility of Pseudomonas aeruginosa to Antibiotics
por: Tetard, Alexandre, et al.
Publicado: (2021)

834. Clinical Outcomes with Carbapenem-Resistant Pseudomonas aeruginosa that Retain Susceptibility to Traditional Antipseudomonal β-lactams: Atlanta, 2016-2018
por: Howard-Anderson, Jessica, et al.
Publicado: (2020)

Susceptibility of Meropenem-Resistant and/or Carbapenemase-Producing Clinical Isolates of Enterobacterales (Enterobacteriaceae) and Pseudomonas aeruginosa to Ceftazidime-Avibactam and Ceftolozane-Tazobactam as Assessed by In Vitro Testing Methods
por: Cortazzo, Venere, et al.
Publicado: (2022)

520. Development of Cefepime-taniborbactam MIC Antimicrobial Susceptibility Test (AST) for Enterobacterales and Pseudomonas aeruginosa on MicroScan Dried Gram-negative MIC Panels
por: Fernandez, Enrique J, et al.
Publicado: (2022)

Feasibility of Using Ceftazidime-Avibactam as a Therapeutic Option for Bloodstream Infections Caused by Multidrug-Resistant Enterobacterales and Pseudomonas aeruginosa Based on Its Susceptibility Profile
por: Priyadarshi, Ketan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lo5978nhgm26e3gtlok7nkbtm7